Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Merck & Co., Eisai's Welireg (belzutifan)-Lenvima (lenvatinib) combo wins FDA approval for second-line clear cell renal cell carcinoma after Ph3
Small molecule, cancer, renal cell carcinoma, HIF-2α inhibitor, combination therapy, tyrosine kinase inhibitor - Read more

Neuraxpharm, Minoryx Therapeutics' Nezglyal (leriglitazone) receives European Commission approval for cerebral adrenoleukodystrophy following Ph2/3 results
Small molecule, neurological, PPAR gamma agonist, cerebral adrenoleukodystrophy, rare disease, pediatric - Read more

Genentech, Earendil Labs partner on AI-driven cancer bispecific antibodies, $55M upfront, $1.5B+ deal
Co-development, oncology, AI/ML, bispecific antibody, milestone payments, royalties - Read more

Boehringer Ingelheim offloads China biologics CDMO unit to Raas Blood Products for up to $3M
Acquisition, manufacturing, antibody, biologics, CDMO - Read more

Novo, Nanexa partner on long-acting obesity injectables with $1.33B deal, $700M in upfront and milestones
Licensing deal, obesity, drug delivery, small molecule, milestone payments - Read more

Ligand Pharmaceuticals, AvenCell Therapeutics enter $47M financing deal to advance next-generation CAR-T therapies
Financing agreement, oncology, cell therapy, CAR-T, royalties, milestone payments - Read more

Cell and Gene Live is a one-day, investor & CEO summit dedicated exclusively to Cell and Gene therapy - the science, the manufacturing, and the investment driving advanced medicines forward. All happening on November 15, 2026.

(Hosted by Onyx at The Shard in London as part of London Life Sciences Week)

Speakers confirmed include:

• Steve Bates, OBE (Chair of the UK's Department of Life Sciences)
• Dr. Erik Wiklund (CEO of Circio)
• Edwin Stone (CEO of Cellular Origins)
+ many more!

Get your tickets here - for TLDR Biotech readers, use code ANIS20 at check-out for 20% off.

J&J, Legend Biotech's Carvykti (cilta-cel) shows 5-year survival benefit in Ph2 multiple myeloma study
Cell therapy, cancer, CAR-T, multiple myeloma, BCMA target - Read more

REGENXBIO reports positive Ph2 three-year durability data for (surabgene lomparvovec) in non-proliferative diabetic retinopathy
Gene therapy, metabolic, AAV vector, diabetic retinopathy, anti-VEGF, suprachoroidal delivery - Read more

ADARx Pharmaceuticals raises $446M IPO, advancing siRNA and complement-mediated disease pipeline
siRNA, rare disease, complement-mediated diseases, hereditary angioedema, clinical-stage - Read more

Kasvu Therapeutics raises €30M ($34.1M) Series A to advance neuroplastogen depression candidate KTX-0141
Neurological, small molecule, depression, neuroplasticity, clinical-stage - Read more

Yale Stress Center receives $10.3M contract to develop AI models for stress-related behavioral health illnesses
AI/ML platform, behavioral health, biomarker discovery, neurological, wearables - Read more

Axio BioPharma raises $2.4M pre-seed funding to develop pharma data connectivity platform
Software platform, manufacturing, data analytics, pharma services - Read more

Lundbeck to relocate U.S. headquarters to Boston, establishing global innovation hub to expand neuroscience and AI capabilities
Neuroscience, neurological, operational, strategic - Read more

Nektar Therapeutics wins $90M jury verdict against Eli Lilly over breached rezpeg partnership agreement
Regulatory T cell therapy, autoimmune, competitive, major transaction - Read more

Novotech acquires Agilex Biolabs from Healius Limited, expanding bioanalytical capabilities in Australia
Acquisition, bioanalytical services, R&D, clinical research - Read more

FDA nominee Heidi Overton affirms vaccines and mifepristone safe and effective at Senate confirmation hearing
Regulatory affairs, vaccines, mifepristone, political interference - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Indivior terminates GABAB PAM alliance with Addex Therapeutics, returning full global rights to addiction and other assets
Termination, research collaboration, small molecule, neurological, addiction, rare disease - Read more

GSK faces "totally unacceptable" misconduct ruling over lack of transparency with UK self-regulatory body
Vaccine, infectious disease, compliance, operational - Read more

Eli Lilly reprimanded by UK watchdog for "promotional" language in orforglipron GLP-1 press release
Small molecule, obesity, regulatory, operational - Read more

FDA issues warning letter to Empower Pharmacy over insanitary GLP-1 compounding conditions
GLP-1 agonist, metabolic disease, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here